You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆匯公告精選(港股)︱山東黃金(01787.HK)盈喜:預期一季度歸母淨利同比增加35.74%到61.45%
格隆匯 04-14 23:11

【今日焦點】

山東黃金(01787.HK)盈喜:預期一季度歸母淨利同比增加35.74%到61.45%

山東黃金(01787.HK)公告,經初步測算,預計2025年第一季度實現歸屬於母公司所有者的淨利潤爲人民幣9.50億元至人民幣11.30億元,與上年同期相比增加人民幣2.50億元到人民幣4.30億元,同比增加35.74%到61.45%。

預計2025年第一季度實現歸屬於母公司所有者的扣除非經常性損益後的淨利潤爲人民幣9.51億元至人民幣11.31億元,與上年同期相比增加人民幣2.42億元到人民幣4.22億元,同比增加34.05%到59.41%。

【重大事項】

映恩生物-B(09606.HK)香港IPO發行價定爲每股94.60港元 淨籌15.1億港元

晉景新能(01783.HK)與晶科訂立諒解備忘錄 將在綠色能源業務領域密切合作

知行科技(01274.HK):首款搭載公司iDC 500行泊一體域控制器的主流國產車型正式上市

英諾賽科(02577.HK)發佈自主開發的1200V氮化鎵(GaN)產品

【財報業績】

遠東宏信(03360.HK)一季度收入及歸屬普通股股東應佔溢利同比微幅增長

【運營數據】

恆鼎實業(01393.HK)第一季度原煤生產總計120.2萬噸 同比增長77%

【醫藥創新】

沛嘉醫療-B(09996.HK):國家藥監局受理TaurusTrio經導管主動脈瓣系統的註冊申請

山東新華製藥股份(00719.HK):氨茶鹼片通過仿製藥一致性評價

石藥集團(01093.HK):SYS6041(抗體偶聯藥物)獲美國臨牀試驗批準

【收購出售】

BRILLIANCE CHI(01114.HK)附屬建議透過公開掛牌方式購買136項機器設備

卓航控股(01865.HK)擬830萬坡元出售Integral Virtue 27%股權

【股權激勵】

西藏水資源(01115.HK)授出4.079億份購股權

藥明合聯(02268.HK)授出539萬股受限制股份

京東方精電(00710.HK)授出合共333.9萬股獎勵股份

【增發供股】

中國智能科技(00464.HK)擬折讓約18.52%配發合共4600萬股 籌資約1000萬港元

【增減持】

驢跡科技(01745.HK)董事會主席及控股股東臧偉仲擬增持公司股份

華營建築(01582.HK)獲執行董事兼主席管滿宇增持50萬股

中國外運(00598.HK)控股股東合計增持5312萬股A股 增持計劃實施完畢

【回購註銷】

周黑鴨(01458.HK)已購回約2.27億股及增加最高1億港元購回資金額度

友邦保險(01299.HK)4月14日耗資2.54億港元回購488萬股

阿里巴巴-W(09988.HK)4月11日耗資1999萬美元回購152.4萬股

匯豐控股(00005.HK)4月11日耗資1.2億港元回購160萬股

美的集團(00300.HK)4月14日耗資6001萬元回購85.78萬股A股

中遠海控(01919.HK)4月14日耗資5568.34萬元回購394.8萬股A股

太古股份公司A(00019.HK)4月14日耗資3020萬港元回購47.6萬股

復星醫藥(02196.HK)4月14日耗資2499.63萬元回購104.17萬股A股

保誠(02378.HK)4月11日耗資190.45萬英鎊回購26萬股

中國外運(00598.HK)4月14日耗資1498萬元回購307萬股A股

太古地產(01972.HK)4月14日耗資955萬港元回購60萬股

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account